Clinical trials: Relapsed Lymphoblastic Leukemia
Lymphocytic Leukemia, Mantle Cell Lymphoma
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
The purpose of this research is to evaluate the use of Rituximab in combination with Revlimid in the treatment of refractory Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT00609869
- Testing
- Lenalidomide, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
T-cell Acute Lymphoblastic Leukemia
CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia
This is a phase I, interventional, single arm, open label, clinical study to evaluate the safety and tolerability of CD5 CAR-T cells in refractory/relapsed CD5+ T-ALL patients who have no available curative treatment options.
- Trial name
- NCT05596266
- Testing
- CD5 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuanwu Hospital, Beijing
T Cell Lymphoblastic Lymphoma
Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL
This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of T cells expressing CD7 chimeric antigen receptors (referred to as "BT-007 CAR-T cells") in patients with relapsed or refractory…
- Trial name
- NCT05554575
- Testing
- BT-007 CD7 CAR-T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Bioceltech Therapeutics, Ltd.
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00818961
- Testing
- alemtuzumab, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northside Hospital, Inc.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have…
- Trial name
- NCT07139873
- Testing
- DZD8586, Bendamustine, Idelalisib
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- Dizal Pharmaceuticals
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL
- Conditions
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma, PTCL
- Trial name
- Phase I/II (NCT06874946)
- Testing
- CD5-targeted CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Chronic Lymphocytic Leukemia, Graft vs Host Disease
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
Cancers of the blood, sometimes referred to as hematologic malignancies, are disorders of bone marrow cells that lead to the failure of the normal function of bone marrow and the uncontrolled growth of cancerous cells in the bone…
- Conditions
- Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hematologic Neoplasm, Multiple Myeloma
- Trial name
- NCT00001873
- Testing
- Isolex 300i plus MoAbs
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
- Trial name
- NCT04808570
- Testing
- TQ-B3525 tablets
- Where
- 9 sites in China
- Volunteers
- 23 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Acute Leukemias of Ambiguous Lineage, Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia
This phase I trial studies the side effects and best dose of entinostat when given together with clofarabine in treating patients with newly diagnosed, relapsed, or refractory poor-risk acute lymphoblastic leukemia or…
- Conditions
- Acute Leukemias of Ambiguous Lineage, Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT01132573
- Testing
- entinostat, clofarabine, pharmacological study
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
- Trial name
- NCT02157324
- Testing
- acalabrutinib, ACP-319
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Acerta Pharma BV
Malignancies, Acute Lymphoblastic Leukemia (ALL)
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary…
- Conditions
- Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma
- Trial name
- NCT03236857
- Testing
- chemotherapy, venetoclax
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 143 people
- Sponsor
- AbbVie
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
This phase I trial is studying the side effects and best dose of methoxyamine when given together with fludarabine phosphate in treating patients with relapsed or refractory hematologic malignancies.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01658319
- Testing
- fludarabine phosphate, methoxyamine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Case Comprehensive Cancer Center
Dual-target CAR-T Cells, B ALL
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia
Prospectively evaluate the safety and effectiveness of CD19/CD22 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.
- Conditions
- Dual-target CAR-T Cells, B ALL, Relapse, Refractory B Acute Lymphoblastic Leukemia
- Trial name
- CAR-T (NCT04723901)
- Testing
- Dual target CAR-T cell therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen University General Hospital
Breast Cancer, Chronic Myeloproliferative Disorders
Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome
RATIONALE: Probiotics, such as Lactobacillus, may be effective in preventing infections in patients with suppressed immune systems.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00946283
- Testing
- Lactobacillus rhamnosus GG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rutgers, The State University of New Jersey
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor (CAR) will be infused back to patients with refractory /relapsed B cell malignancies, including lymphoma and leukemia.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
- Trial name
- NCT03191773
- Testing
- Drugs and anti-CD19 CAR transduced T cells
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory lymphoma or leukemia.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT00005786
- Testing
- arsenic trioxide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20).
- Conditions
- Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
- Trial name
- EPCORE™ CLL-1 (NCT04623541)
- Testing
- Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax
- Where
- 81 sites in United States, Australia and 10 more
- Volunteers
- 194 people
- Sponsor
- Genmab
Leukemia
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004905
- Testing
- filgrastim, recombinant interferon alfa, cyclophosphamide
- Where
- 3 sites in United States
- Sponsor
- Loyola University
Leukemia
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002588
- Testing
- etoposide, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.